Placebo Response Significant in Overactive Bladder
The placebo response is statistically, and possibly clinically, significant in patients with OAB, according to authors of a new systematic review.
The placebo response is statistically, and possibly clinically, significant in patients with OAB, according to authors of a new systematic review.
In a real-world study, only half of patients continued with long-term maintenance percutaneous tibial nerve stimulation after the initial 12 weeks.
Responses to the OAB-BAT complement information from bladder diaries for monitoring overactive bladder outcomes, according to investigators.
Experiencing any urinary incontinence was associated with bother regardless of a man’s race.
The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent catheterization.
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
Clinical and urodynamic criteria for antimuscarinic nonresponse in men are needed along with more quality research on treatment alternatives.
Researchers conducted meta-analyses to investigate the real rates of persistence and adherence to overactive bladder drug therapies and moderating factors.
Higher cardiovascular morbidity was associated with more severe urge urinary incontinence and worse quality of life.
A meta-analysis evaluated the efficacy and safety of imidafenacin for overactive bladder induced by benign prostatic hyperplasia.